Abstract

Objective: To summarize the incidence of malignancies by NMSC and malignancies other than NMSC/cervical cancer in situ, using pooled VOYAGE1&2 data through 4-years of guselkumab (GUS) treatment; results were compared with expected rates in the general USpopulation.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call